Detalhe da pesquisa
1.
Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework.
J Natl Compr Canc Netw
; 19(7): 815-820, 2021 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33636693
2.
Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
J Natl Compr Canc Netw
; 18(3): 278-285, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135516
3.
Evaluation of the impact of patient involvement in health technology assessments: A scoping review.
Int J Technol Assess Health Care
; 36(3): 217-223, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383420
4.
Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
J Natl Compr Canc Netw
; 17(12): 1489-1496, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31805528
5.
Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.
Crit Rev Oncol Hematol
; 173: 103660, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35341985
6.
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
JAMA Netw Open
; 4(2): e2033004, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570573
7.
Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
Crit Rev Oncol Hematol
; 145: 102817, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31955005